Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 571 participants.

Also called NCT03285594

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 571 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03285594
  • EudraCT 2016-001804-43
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Czechia, France, Hungary, Slovakia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03285594. Randomized; double masking; primary purpose treatment. Start 2017-09-15 (actual); primary completion 2019-09-17 (actual). Results posted on 2021-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Acronym
SOTA-INS
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Insulin glargine (HOE901)
Intervention (Drug)
Placebo
Intervention (Drug)
Oral Antidiabetes Drugs (OADs)
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03285594
Content hash
4e05a69877c866e080be91349ec2fc7aa124d784fb8efe0627d816db5f133dbc